癌症免疫疗法：超越现有疫苗
Cancer immunotherapy: moving beyond current vaccines.
作者信息
Rosenberg Steven A, Yang James C, Restifo Nicholas P
机构信息
Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892-1502, USA.
出版信息
Nat Med. 2004 Sep;10(9):909-15. doi: 10.1038/nm1100.
Abstract
Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.
摘要
在过去十年中，肿瘤免疫学领域取得了巨大进展，但对当前可用癌症疫苗方法临床应用的乐观态度更多地基于替代终点而非临床肿瘤消退。在我们对440名患者的癌症疫苗试验中，客观缓解率很低（2.6%），与其他人获得的结果相当。我们在此讨论癌症疫苗试验的结果，并强调在临床前和临床模型中介导癌症消退的替代策略。
相似文献
1
Cancer immunotherapy: moving beyond current vaccines.癌症免疫疗法：超越现有疫苗
Nat Med. 2004 Sep;10(9):909-15. doi: 10.1038/nm1100.
2
Cancer vaccines: pessimism in check.癌症疫苗：谨慎看待悲观情绪。
Nat Med. 2004 Dec;10(12):1278-9; author reply 1279-80. doi: 10.1038/nm1204-1278.
3
Therapeutic cancer vaccines: From initial findings to prospects.治疗性癌症疫苗：从初步发现到展望。
Immunol Lett. 2018 Apr;196:11-21. doi: 10.1016/j.imlet.2018.01.011. Epub 2018 Feb 4.
4
Immunotherapy of metastasis.转移瘤的免疫治疗。
Surg Oncol Clin N Am. 2001 Apr;10(2):433-47, xi.
5
Cancer vaccines: pessimism in check.癌症疫苗：抑制悲观情绪。
Nat Med. 2004 Dec;10(12):1279; author reply 1279-80. doi: 10.1038/nm1204-1279a.
6
Cancer vaccines. Any future?癌症疫苗。有未来吗？
Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):249-59. doi: 10.1007/s00005-011-0129-y. Epub 2011 Jun 5.
7
Are peptide vaccines viable in combination with other cancer immunotherapies?肽疫苗与其他癌症免疫疗法联合使用是否可行？
Future Oncol. 2017 Aug;13(18):1577-1580. doi: 10.2217/fon-2017-0136. Epub 2017 Aug 4.
8
Advances in personalized neoantigen vaccines for cancer immunotherapy.癌症免疫治疗中个性化新抗原疫苗的进展。
Biosci Trends. 2020 Nov 4;14(5):349-353. doi: 10.5582/bst.2020.03267. Epub 2020 Sep 10.
9
Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I.癌症的细胞免疫疗法：当前概念与临床展望——治疗性癌症疫苗的科学基础与方法。第一部分。
Clin Oncol (R Coll Radiol). 2004 Aug;16(5):356-65. doi: 10.1016/j.clon.2004.03.013.
10
Immune based therapies in cancer.癌症的免疫疗法
Histol Histopathol. 2007 Jun;22(6):687-96. doi: 10.14670/HH-22.687.
引用本文的文献
1
Mesenchymal stromal cells 2.0: thinking outside the box.间充质基质细胞2.0：跳出框框思考。
Front Immunol. 2025 Aug 20;16:1657048. doi: 10.3389/fimmu.2025.1657048. eCollection 2025.
2
Dynamic of competitive Lotka-Volterra model for tumor-host systems under constant or periodic perturbation: Implications for the therapy of cancer.恒定或周期性扰动下肿瘤-宿主系统竞争型Lotka-Volterra模型的动力学：对癌症治疗的启示
PLoS One. 2025 Aug 25;20(8):e0329087. doi: 10.1371/journal.pone.0329087. eCollection 2025.
3
The Mitigating Effect of Combined Glucocorticoids with Immune Checkpoint Inhibitors on Lymphocyte Activation Gene-3 and Programmed Death-1 Expression.糖皮质激素与免疫检查点抑制剂联合使用对淋巴细胞激活基因-3和程序性死亡-1表达的缓解作用
Eur J Immunol. 2025 Aug;55(8):e70033. doi: 10.1002/eji.70033.
4
Nanotechnology for immuno-oncology.免疫肿瘤学的纳米技术
Nat Cancer. 2025 Aug 7. doi: 10.1038/s43018-025-01025-x.
5
A Milestone in the Shift from "Passive Killing" to "Active Immunomodulation" in Cancer Treatment-Progress in Melanoma Vaccine Research.癌症治疗从“被动杀伤”到“主动免疫调节”转变中的一个里程碑——黑色素瘤疫苗研究进展
Curr Treat Options Oncol. 2025 Jul 17. doi: 10.1007/s11864-025-01340-6.
6
Eliciting antitumor immunity via therapeutic cancer vaccines.通过治疗性癌症疫苗激发抗肿瘤免疫力。
Cell Mol Immunol. 2025 Jul 9. doi: 10.1038/s41423-025-01316-4.
7
Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects.肺癌中基于新抗原的免疫疗法：进展、挑战与前景
Cancers (Basel). 2025 Jun 12;17(12):1953. doi: 10.3390/cancers17121953.
8
In Situ Vaccination with Poly-ICLC Combined with Systemic Nivolumab for the Treatment of Unresectable Hepatocellular Carcinoma.聚肌胞苷酸-聚左旋赖氨酸-羧甲基纤维素（Poly-ICLC）原位接种联合纳武利尤单抗全身治疗不可切除肝细胞癌
J Hepatocell Carcinoma. 2025 Jun 14;12:1191-1204. doi: 10.2147/JHC.S520710. eCollection 2025.
9
Interplay between cancer-associated fibroblasts and dendritic cells: implications for tumor immunity.癌症相关成纤维细胞与树突状细胞之间的相互作用：对肿瘤免疫的影响
Front Immunol. 2025 May 16;16:1515390. doi: 10.3389/fimmu.2025.1515390. eCollection 2025.
10
Pyroptosis-Inducing Platinum(IV) Prodrugs via GSDME Pathway for Chemoimmunotherapy and Metastasis Inhibition in Triple-Negative Breast Cancer.通过GSDME途径诱导细胞焦亡的铂（IV）前药用于三阴性乳腺癌的化学免疫治疗和转移抑制
Adv Sci (Weinh). 2025 May 28:e05567. doi: 10.1002/advs.202505567.
本文引用的文献
1
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients.一项针对结直肠癌患者的以细胞毒性T淋巴细胞前体为导向的肽疫苗的I期试验。
Br J Cancer. 2004 Apr 5;90(7):1334-42. doi: 10.1038/sj.bjc.6601711.
2
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.粒细胞-巨噬细胞集落刺激因子基因修饰的自体肿瘤疫苗用于非小细胞肺癌治疗
J Natl Cancer Inst. 2004 Feb 18;96(4):326-31. doi: 10.1093/jnci/djh028.
3
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.癌症患者接种针对端粒酶的疫苗可诱导具有功能的抗肿瘤CD8 + T淋巴细胞。
Clin Cancer Res. 2004 Feb 1;10(3):828-39. doi: 10.1158/1078-0432.ccr-0620-3.
4
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.白细胞介素-15增强肿瘤反应性CD8 + T细胞的体内抗肿瘤活性。
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74. doi: 10.1073/pnas.0307298101. Epub 2004 Feb 4.
5
The first 1000 dendritic cell vaccinees.首批1000名接受树突状细胞疫苗接种者。
Cancer Invest. 2003;21(6):873-86. doi: 10.1081/cnv-120025091.
6
Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma.源自黑色素瘤裂解物的大型多价免疫原在播散性黑色素瘤患者中的I期试验。
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):76-83. doi: 10.1158/1078-0432.ccr-0689-3.
7
Control of autoimmunity by naturally arising regulatory CD4+ T cells.天然产生的调节性CD4 + T细胞对自身免疫的控制。
Adv Immunol. 2003;81:331-71. doi: 10.1016/s0065-2776(03)81008-8.
8
Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.树突状细胞疫苗治疗播散性黑色素瘤患者的I/II期研究。
Cancer Immunol Immunother. 2004 Feb;53(2):125-34. doi: 10.1007/s00262-003-0429-0. Epub 2003 Nov 5.
9
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.一项随机II期试验的临床和免疫学结果，该试验采用四种黑色素瘤肽进行疫苗接种，这些肽要么与粒细胞-巨噬细胞集落刺激因子联合作为佐剂给药，要么负载于树突状细胞上。
J Clin Oncol. 2003 Nov 1;21(21):4016-26. doi: 10.1200/JCO.2003.10.005.
10
Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.转移性结直肠癌肝切除术后接种自体肿瘤来源的热休克蛋白gp96。
Clin Cancer Res. 2003 Aug 15;9(9):3235-45.
Zotero 插件